Effect of regulatory focus on performance and evaluation of training in organizations context

La formación empresarial no siempre consigue los objetivos deseados. Con el propósito de evaluar este problema, el presente estudio examinó en qué medida el rendimiento y la satisfacción en una tarea de formación en idiomas podían cambiar en función del foco regulatorio con el que se afronta dicha tarea. Se manipuló sutilmente el enfoque con el que los empleados de una empresa grande abordaron la tarea de formación, con lo que se crearon tres tipos de instrucciones: planteamiento de promoción, planteamiento de prevención y grupo control. Se evaluó la influencia de esta variable independiente (el foco regulatorio) en relación con el rendimiento y las percepciones de los trabajadores en la tarea. Los resultados mostraron que el foco regulatorio influyó en la satisfacción y el rendimiento percibido, pero no en el rendimiento objetivo. Este trabajo muestra que el efecto de la formación en un contexto organizacional varía en función del enfoque motivacionalTraining programs are not always successful in achieving desired goals. In order to address this issue, the present research examined the extent to which performance and satisfaction in a language training task could change as a function of regulatory focus for task coping. The approach with which employees from a large company addressed the training task was subtly manipulated, creating three types of instructions: promotion approach, prevention approach, and control group. The influence of this independent variable (regulatory focus) was evaluated with regard to employees’ performance and perceptions. Results showed that regulatory focus affected satisfaction and perceived performance, but not objective performance. Th is work reveals that the training effect in an organizational context varies as a function of motivational focu

Osteonecrosis of the jaw as an adverse bisphosphonate event : Three cases of bone metastatic prostate cancer patients treated with zoledronic acid

Bisphosphonates offer a significant improvement in the quality of life for cancer patients; these potent inhibitors of bone resorption have been shown to markedly reduce the morbidity frequently resulting from bone metastases. Despite the success of bisphosphonates as therapeutic agents, however, toxicity in the form of osteonecrosis of the jaw (ONJ) is a rare complication whose incidence rate has climbed in recent years. ONJ is defined as an unexpected development of necrotic bone in the oral cavity, and is commonly associated with administration of the bisphosphonates Pamidronate and Zoledronate. Clinical features include local pain, soft-tissue swelling, and/or loose teeth; ONJ is also often correlated with previous dental procedures, such as tooth extractions, during biphosphonate therapy. Although additional risk factors--such as corticosteroids, chemotherapy, radiotherapy, trauma or infection?exhibit etiological associations with ONJ, the real pathobiology has not yet been fully elucidated. Here we report our findings on all 2005 OJN cases presented at our institution resulting from bone metastatic prostate cancer treated with zoledronic acid. The incidence of ONJ is nearly 3% (3 out of 104) in these patients

Leges Romanae on‐line: diseño colaborativo y multidisciplinar de recursos educativos en abierto

Fac. de DerechoFALSEsubmitte

Cáncer de pulmón no microcítico: quimioterapia y otros tratamientos sistémicos

Lung cancer is the most frequent neoplasia in industrialized countries and the leading cause of cancer death worldwide. Non-small cell lung cancer (NSCLC) accounts for 75-80% of lung carcinomas. Approximately one-third of these patients are diagnosed of locally advanced disease (Stage III of TNM staging system). Although surgery is the optimal treatment strategy, even in patients with stage I disease, approximately one third of them will die within 5 years, due to relapses and distant metastases. Several studies have explored the impact of neo-adyuvant chemotherapy in free disease survival and overall survival and adjuvant chemotherapy trials have been conducted to eliminate occult micrometastases and improve overall survival. In advanced disease, primary goals of therapy are palliation of symptoms as well as improvements in quality of life without high treatment-related toxicity

The MORFO3D foot database

The final publication is available at Springer via http://dx.doi.org/10.1007/11492542_80A foot database comprising 3D foot shapes and footwear fitting reports of more than 300 participants is presented. It was primarily acquired to study footwear fitting, though it can also be used to analyse anatomical features of the foot. In fact, we present a technique for automatic detection of several foot anatomical landmarks, together with some empirical results.Work supported by the “Agència Valenciana de Ciència i Tecnologia” under grant GRUPOS03/031 and the Spanish projects DPI2001-0880-CO2-01 and DPI2001-0880-CO2-02.García Hernández, J.; Heras Barberá, SM.; Juan Císcar, A.; Paredes Palacios, R.; Nácher Rodríguez, B.; Alemany, S.; Alcántara, E.... (2005). The MORFO3D foot database. En Pattern Recognition and Image Analysis: Second Iberian Conference, IbPRIA 2005, Estoril, Portugal, June 7-9, 2005, Proceedings, Part II. Springer Verlag (Germany). 658-665. https://doi.org/10.1007/11492542_80S658665I-ware laboratory, http://www.i-ware.co.jp/Goonetilleke, R.S., Luximon, A.: Designing for comfort: a footwear application. In: Proceedings of the Computer-Aided Ergonomics and Safety Conference 2001, July 28-August 2 (2001) Plenary session paperNacher, B., Alcántara, E., Alemany, S., García-Hernández, J., Juan, A.: 3d foot digitalizing and its application to footwear fitting. In: Proc. of 3D Modelling (2004

Design and Preparation of Pharmaceutical Solid Dosage Forms of Benznidazole for the Treatment of Chagas Disease

INTRODUCCIÓN: En Argentina se emplea el benznidazol como terapéutica de primera línea para el tratamiento etiológico del Chagas. Desde su lanzamiento (hace más de 40 años), sólo se dispone de comprimidos convencionales de 100 mg; no se han desarrollado nuevas formas farmacéuticas que aumenten la eficacia y seguridad, ni alternativas con dosis pediátricas. OBJETIVOS: Desarrollar formas farmacéuticas de benznidazol que ofrezcan ventajas farmacoterapéuticas. MÉTODOS: Preformulación y diseño de nuevas formulaciones de benznidazol, con caracterización físico-química y selección de las formulaciones más favorables. Frente a la discontinuidad de producción del ingrediente activo benznidazol, se desarrolló una metodología de extracción a partir de la única alternativa comercial disponible. RESULTADOS: Se obtuvieron nuevas formulaciones de comprimidos de 50 y 100 mg de benznidazol, con una rápida disolución del producto de referencia. Además, se obtuvieron formulaciones masticables de 50 mg bajo la forma de hidrogeles azucarados, con un efectivo enmascaramiento del mal sabor. Todas las formulaciones cumplieron los ensayos de evaluación de las propiedades farmacotécnicas y biofarmacéuticas, superando los perfiles de referencia. CONCLUSIONES: Se desarrollaron nuevas alternativas farmacéuticas de benznidazol de rápida disolución, que podrían mejorar el tratamiento etiológico de la enfermedad (especialmente en pediatría) y convertirse en herramientas aptas para su explotación comercial.INTRODUCTION: In Argentina, benznidazole is the drug of choice for the etiological treatment of Chagas disease. Since it was launched (more than 40 years ago), there are only 100 mg tablets available; the development included neither new pharmaceutical forms improving efficacy and safety, nor a pediatric dosage option. OBJECTIVES: To develop pharmaceutical forms of benznidazole with pharmacotherapeutic advantages. METHODS: Preformulation and design of new formulations of benznidazole, with physicochemical characterization and selection of the most favorable formulations. Due to the discontinuity in the production of the active ingredient benznidazole, a specific methodology was developed in order to obtain it from the only commercially available alternative. RESULTS: New benznidazole tablet formulations were obtained (50 and 100 mg), with a rapid dissolution of the reference product, as well as chewable formulations of 50 mg as sugar hydrogels featuring an effective taste masking. All formulations passed the evaluation tests for pharmacotechnical and biopharmaceutical properties, outperforming the reference profiles. CONCLUSIONS: New fast-dissolving pharmaceutical dosage forms of benznidazole were developed, which could improve the etiological treatment of the disease (especially in the pediatric field) and become a proper tool for its commercial exploitationFil: Tarragona, Sonia. Fundación Mundo Sano; ArgentinaFil: Salomon, Claudio Javier. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Rosario. Instituto de Química Rosario; ArgentinaFil: Jimenez Kairuz, Alvaro Federico. Universidad Nacional de Cordoba. Facultad de Ciencias Quimicas. Departamento de Farmacia; ArgentinaFil: Lamas, Maria Celina. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Rosario. Instituto de Química Rosario; ArgentinaFil: Orlandi, Silvina. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas; ArgentinaFil: Leonardi, Darío. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Rosario. Instituto de Química Rosario; ArgentinaFil: Maggia, Norma Graciela. Universidad Nacional de Cordoba. Facultad de Cs.quimicas; ArgentinaFil: Paredes, Alejandro Javier. Universidad Nacional de Cordoba. Facultad de Cs.quimicas; ArgentinaFil: Romañuk, Carolina Beatriz. Universidad Nacional de Cordoba. Facultad de Cs.quimicas; ArgentinaFil: García, Mónica Cristina. Universidad Nacional de Cordoba. Facultad de Cs.quimicas; Argentin

Roma en Red: docencia transversal entre 3 disciplinas y aprendizaje colaborativo para la creación y difusión on-line de contenidos didácticos comunes

Depto. de Derecho Romano e Historia del DerechoFac. de DerechoFALSEsubmitte

safety and effectiveness of regorafenib in patients with metastatic colorectal cancer in routine clinical practice in the prospective observational correlate study

Abstract Background Regorafenib prolonged overall survival (OS) versus placebo in patients with treatment-refractory metastatic colorectal cancer (mCRC) in phase III trials. We conducted an observational study of regorafenib for patients with mCRC in real-world clinical practice. Methods The international, prospective, CORRELATE study recruited patients with mCRC previously treated with approved therapies, for whom the decision to treat with regorafenib was made by the treating physician according to the local health authority approved label. The primary objective was safety, assessed by treatment-emergent adverse events (TEAEs; National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.03). Results A total of 1037 patients were treated. The median age was 65 years (range: 24–93); 87% of patients had Eastern Cooperative Oncology Group performance status 0–1, 56% of patients had KRAS, 7% had NRAS and 4% had BRAF mutations. The initial regorafenib dose was 160 mg/day in 57% of patients. The most common grade III or IV drug-related TEAEs were fatigue (9%), hand–foot skin reaction (7%) and hypertension (6%). Drug-related grade V (fatal) TEAEs occurred in 1% of patients. Dose reductions for drug-related TEAEs occurred in 24% of patients. Median OS was 7.7 months (95% confidence interval [CI]: 7.2–8.3), and median progression-free survival (PFS) was 2.9 months (95% CI: 2.8–3.0). Conclusions In this real-world, observational study of patients with mCRC, the regorafenib toxicity profile was similar to that reported in phase III trials. The starting dose for almost half of patients was less than the approved 160-mg dose, and the median OS and PFS were in the range observed in phase III trials. Trial registration: NCT02042144

Virological and immunological outcome of treatment interruption in HIV-1-infected subjects vaccinated with MVA-B

The most relevant endpoint in therapeutic HIV vaccination is the assessment of time to viral rebound or duration of sustained control of low-level viremia upon cART treatment cessation. Structured treatment interruptions (STI) are however not without risk to the patient and reliable predictors of viral rebound/control after therapeutic HIV-1 vaccination are urgently needed to ensure patient safety and guide therapeutic vaccine development. Here, we integrated immunological and virological parameters together with viral rebound dynamics after STI in a phase I therapeutic vaccine trial of a polyvalent MVA-B vaccine candidate to define predictors of viral control. Clinical parameters, proviral DNA, host HLA genetics and measures of humoral and cellular immunity were evaluated. A sieve effect analysis was conducted comparing pre-treatment viral sequences to breakthrough viruses after STI. Our results show that a reduced proviral HIV-1 DNA at study entry was independently associated with two virological parameters, delayed HIV-1 RNA rebound (p = 0.029) and lower peak viremia after treatment cessation (p = 0.019). Reduced peak viremia was also positively correlated with a decreased number of HLA class I allele associated polymorphisms in Gag sequences in the rebounding virus population (p = 0.012). Our findings suggest that proviral DNA levels and the number of HLA-associated Gag polymorphisms may have an impact on the clinical outcome of STI. Incorporation of these parameters in future therapeutic vaccine trials may guide refined immunogen design and help conduct safer STI approaches